Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-04

Study Completion Date

2020-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE. Study population will be selected as part of usual care as eligible for home treatment. Study personnel will travel to participating institutions to qualify the sites, deliver a Powerpoint® lecture to introduce the protocol, meet and train site principal investigators, emergency physicians and research personnel on the implementation of the protocol as part of usual clinical care, and data collection methods for a quality assurance registry with plans to use the data collected in this registry in future publications. Follow-up will be 30 days using medical records and/or telephone interview to assess for primary outcomes of bleeding or VTE recurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201

Venous Thrombosis

COMPLETED PHASE3

Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant

NCT02079584

Venous Thromboembolism

COMPLETED

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218

Venous Thromboembolism (VTE)

COMPLETED PHASE3

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002

Venous Thrombosis Pulmonary Embolism

COMPLETED PHASE3

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00633893

Venous Thrombosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apixaban for VTE

Apixaban

Intervention Type DRUG

Apixaban as standard of care for VTE

Rivaroxaban for VTE

Rivaroxaban

Intervention Type DRUG

Rivaroxaban as standard of care for VTE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban

Apixaban as standard of care for VTE

Intervention Type DRUG

Rivaroxaban

Rivaroxaban as standard of care for VTE

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must be low risk, as defined by either A or B below:

A. The modified Hestia criteria:
* Systolic blood pressure \> 100 mm Hg
* No thrombolysis needed
* No active bleeding
* SaO2 \>94% while breathing room air
* Not already anticoagulated
* No more than two doses of IV narcotics in the emergency department
* Other medical or social reasons to admit
* Creatinine clearance \>30mL/min
* Not pregnant, severe liver disease or heparin induced thrombocytopenia OR

B. The physician opinion that a patients' overall social and medical situation is favorable for home treatment and the patient has a zero score on the simplified pulmonary embolism severity index (sPESI).

All of the following must true:
* Age \< 81 years
* No history of cancer
* No history of heart failure or chronic lung disease
* Pulse \< 110 beats/min
* SBP \> 99 mm Hg
* O2 sat \>89%%

We have chosen either criteria because both have been found equal in terms of safety for outpatient treatment of PE.6,22 Hestia includes implicit questions that most emergency physicians would use as criteria for discharge (e.g., overall medical status and social situation), whereas sPESI does not. For that reason, we have added the additional gestalt assessment question about physician discretion.
2. Patients must be discharged in \<24 hours after triage in an ED visit with diagnosis of VTE using objective criteria in the emergency department.

Exclusion Criteria

* VTE diagnosis while taking anticoagulants with evidence of compliance (e.g., physician opinion that patient is taking a Eliquis®, Xarelto® or Pradaxa®, low molecular weight heparin injections or warfarin as prescribed for any condition)
* Sensitivity or contraindication to use of apixaban
* Troponin assay value, drawn as part of usual care and found to be positive, using local standards
* High risk for hemorrhage defined by a score\>1.5 using the method of Ruiz Gimenez.3 (Note that several criteria are already excluded by Hestia):

Recent major bleeding, 2 points Creatinine levels \>1.2 mg/dl, 1.5 points Anemia, 1.5 points Cancer, 1 point Clinically overt PE, 1 point Age \>75 years, 1 point

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No